Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Cytarabine MeSH Descriptor Data 2025


MeSH Heading
Cytarabine
Tree Number(s)
D03.383.742.680.245.453
D13.570.065.300
D13.570.685.245.453
Unique ID
D003561
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D003561
Scope Note
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Entry Term(s)
Ara-C
Arabinofuranosylcytosine
Arabinosylcytosine
Aracytidine
Aracytine
Cytarabine Hydrochloride
Cytonal
Cytosar
Cytosar-U
Cytosine Arabinoside
beta-Ara C
Pharm Action
Antimetabolites, Antineoplastic
Antiviral Agents
Immunosuppressive Agents
Registry Numbers
04079A1RDZ
33K3DB6591
0
Related Numbers
147-94-4
33K3DB6591
69-74-9
CAS Type 1 Name
2(1H)-Pyrimidinone, 4-amino-1-beta-D-arabinofuranosyl-
NLM Classification #
QV 269
See Also
Decitabine
Public MeSH Note
1966
History Note
1966
Date Established
1966/01/01
Date of Entry
1999/01/01
Revision Date
2018/02/28
Cytarabine Preferred
Cytarabine Hydrochloride Narrower
Cytosar Narrower
beta-Ara C Narrower
Aracytine Narrower
Ara-C Narrower
Cytonal Narrower
page delivered in 0.119s